Beta-amyloid imaging with florbetaben
Clinical and Translational Imaging · 2015-02 · 3 (1) · 13-26
DOI: 10.1007/s40336-015-0102-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Imaging, online erschienen am 12.02.2015. Verfasst von Osama Sabri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leipzig University, Leipzig, Germany. Die Arbeit wurde bisher 161-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative that was developed as a positron emission tomography (PET) tracer for routine clinical application to visualize β-amyloid plaques in the Alzheimer's disease (AD) brain. The tracer successfully completed a global multicenter phase 0-III development program and was, as a consequence, recently approved by the US Food and Drug Administration and the European Medicines Agency. This review provides an overview on the florbetaben tracer characteristics and preclinical data leading to its human testing. Further, the favorable results of human pharmacokinetics, safety, and dosimetry evaluation of florbetaben are presented. Next, the results of the clinical testing of florbetaben are discussed, in which the tracer was shown to sensitively and specifically detect β-amyloid neuritic plaques, as evidenced by employing different gold standards (from clinical diagnosis to post mortem histopathology). The potential of florbetaben to predict AD dementia in cases of mild cognitive impairment and to assist in the differential diagnosis in cases of dementia is also described. Finally, potential clinical impact and clinical routine PET image acquisition and analysis protocols for florbetaben are discussed. Taken together, the evidence shows that florbetaben is a valuable β-amyloid-targeting PET tracer in the clinic with great potential to serve as a biomarker supporting clinical AD diagnosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leipzig University, Leipzig, Germany.
- Institute of Neurodegenerative Disorders, New Haven, CT USA.
- University of Melbourne, Heidelberg, Australia.
Zitieren
APA
Sabri, O., Seibyl, J., Rowe, C., & Barthel, H. (2015). Beta-amyloid imaging with florbetaben. Clinical and Translational Imaging, 3(1), 13-26. https://doi.org/10.1007/s40336-015-0102-6
Vancouver
Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clinical and Translational Imaging. 2015;3(1):13-26. doi:10.1007/s40336-015-0102-6
BibTeX
@article{Sabri2015,
author = {Sabri, Osama and Seibyl, John and Rowe, Christopher and Barthel, Henryk},
title = {Beta-amyloid imaging with florbetaben},
journal = {Clinical and Translational Imaging},
year = {2015},
volume = {3},
number = {1},
pages = {13--26},
doi = {10.1007/s40336-015-0102-6}
}
EUVIMED